Sumitomo Pharma's Gemtesa (vibegron) has been approved by the U.S. Food and Drug Administration for men with overactive ...

Gemtesa (vibegron) has been approved by the U.S. Food and Drug Administration for men with overactive bladder (OAB) s ...

While it is clear that men with lower urinary ... inability to differentiate between symptoms attributable to detrusor overactivity (DO) and those caused by bladder-outlet obstruction (BOO ...

An overactive bladder may be temporary or become a chronic condition. How long the symptoms last may depend on factors like the underlying cause and treatment adherence. Some conditions may cause ...

THURSDAY, Jan. 2, 2025 (HealthDay News) — Gemtesa (vibegron) has been approved by the U.S. Food and Drug Administration for men with overactive bladder (OAB) symptoms receiving pharmacologic therapy ...

Discover how cold weather can trigger prostate problems in men over 60, including frequent urination, hormonal changes, and ...

Overactive bladder (OAB) is a group of symptoms that are not usually life-threatening but can significantly decrease productivity and quality of life. The condition is characterized by the sudden need ...

The FDA has approved Gemtesa® for men with overactive bladder symptoms receiving pharmacological therapy for BPH.

You may be struggling with urinary symptoms and think overactive bladder (OAB) is the cause. Or, your health care provider may have ... This urge may be accompanied by urine leakage in some cases.